 |
196 Products |  |
52 Diseases | | 196 Products |
|
3529 Trials |  |
15381 News |  |
| «12...1920212223242526272829...208209» |
- | cisplatin / Generic mfg., AiRuiKa (camrelizumab) / HLB Bio Group, albumin-bound paclitaxel / Generic mfg.
Journal: Neoadjuvant chemoimmunotherapy in HPV-associated vulvar and vaginal squamous cell carcinoma with PD-L1 CPS (Pubmed Central) - Oct 31, 2025
Two biopsy-confirmed HPV-associated vulvar/vaginal SCC cases with inguinal lymph node metastases (both PD-L1 CPS
- | Avastin (bevacizumab) / Roche, AiRuiKa (camrelizumab) / HLB Bio Group
Journal, PD(L)-1 Biomarker, IO biomarker: Analysis of risk factors and prognostic prediction in advanced colorectal cancer undergoing immunotherapy combined with targeted therapy. (Pubmed Central) - Oct 31, 2025
This study highlights the prognostic significance of both clinical and inflammatory markers in pMMR advanced colorectal cancer undergoing immunotherapy combined with targeted therapy. The developed nomogram facilitates individualized survival prediction, offering clinicians a practical tool to tailor treatment and follow-up strategies for improved patient management.
- | Kinedak (epalrestat) / Ono Pharma, famitinib (SHR 1020) / Jiangsu Hengrui Pharma
New P2 trial: Exploring the efficacy and safety of famitinib combined with epalrestat and torivirine in the treatment of advanced and recurrent/metastatic cervical cancer (EUDRACT) - Oct 31, 2025
P2, N=90, Not yet recruiting, Sponsor: Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine; Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of
- | Hengqu (hetrombopag) / Jiangsu Hengrui Pharma
New P4 trial: Single arm, prospective clinical study on the application of Haiqupopa ethanolamine tablets in the treatment of thrombocytopenia (CTIT) caused by tumor therapy (EUDRACT) - Oct 31, 2025
P4, N=42, Not yet recruiting, Sponsor: Henan Cancer Hospital; Henan Cancer Hospital
- | AiTan (rivoceranib) / HLB Bio Group, AiRuiLi (adebrelimab) / Jiangsu Hengrui Pharma
New trial, Platinum resistant: A Phase II Study of Induction with Immunotherapy, Targeted Therapy, and Chemotherapy, Followed by Maintenance with Immunotherapy, Targeted Therapy, and a PARP Inhibitor in Platinum-Resistant Ovarian Cancer (EUDRACT) - Oct 31, 2025
P=N/A, N=32, Not yet recruiting, Sponsor: First Hospital Of Nanping; First Hospital Of Nanping
- | AiSuTe (tegileridine) / Jiangsu Hengrui Pharma
New trial: The influence of tegileridine fumarate injection on postoperative inflammatory response and gastrointestinal function in patients undergoing laparoscopic cholecystectomy (EUDRACT) - Oct 31, 2025
P=N/A, N=80, Not yet recruiting, Sponsor: Jingmen People's Hospital; Jingmen People's Hospital
- | AiSuTe (tegileridine) / Jiangsu Hengrui Pharma
New trial: Clinical Study on the Efficacy and Safety of Teglidine Fumarate for Postoperative Analgesia in Orthopedic Surgery (EUDRACT) - Oct 31, 2025
P=N/A, N=120, Not yet recruiting, Sponsor: Ningbo Medical Center Lihuili Hospital; Ningbo Medical Center Lihuili Hospital
- | AiRuiLi (adebrelimab) / Jiangsu Hengrui Pharma
New P4 trial: Adebrelimab combined with etoposide plus platinum followed by adebrelimab and etoposide soft capsules for maintenance treatment of extensive-stage small cell lung cancer: a single-arm phase II trial (EUDRACT) - Oct 31, 2025
P4, N=40, Recruiting, Sponsor: Jiangsu Cancer Hospital; Jiangsu Cancer Hospital
- | AiRuiKang (dalpiciclib) / Jiangsu Hengrui Pharma, AiRuiYi (fluzoparib) / Jiangsu Hengrui Pharma
New trial: Clinical Study of Fluzoparib Combined with Dalpiciclib and Endocrine Neoadjuvant Therapy for gBRCA-Mutated HR+/HER2- Early-Stage Breast Cancer (EUDRACT) - Oct 31, 2025
P=N/A, N=30, Not yet recruiting, Sponsor: Harbin Medical University Affiliated Cancer Hospital; Harbin Medical University Affiliated Cancer Hospital
- | zeprumetostat (SHR-2554) / Treeline Biosci
New P2 trial: A Multicenter, Open-Label Phase II Clinical Study Evaluating the Safety, Tolerability, and Efficacy of SHR2554 Tablets in Combination with Other Antitumor Therapies in Patients with Locally Advanced Unresectable or Metastatic Gastric or Gastro-oesophageal Junction Adenocarcinoma (EUDRACT) - Oct 31, 2025
P2, N=366, Recruiting, Sponsor: Harbin Medical University Cancer Hospital; Harbin Medical University Cancer Hospital
- | Tevimbra (tislelizumab-jsgr) / BeOne Medicines, AiTan (rivoceranib) / HLB Bio Group
New P2 trial: A multicenter, prospective, randomized, controlled, open-label clinical study on the efficacy and safety of low-dose apatinib combined with tislelizumab and mXELOX regimen as first-line treatment for elderly patients with advanced gastric/gastroesophageal junction adenocarcinoma (EUDRACT) - Oct 31, 2025
P2, N=86, Not yet recruiting, Sponsor: Jiangsu Province Hospital; Jiangsu Province Hospital
- | AiSuTe (tegileridine) / Jiangsu Hengrui Pharma
New trial: The analgesic effect of tegileridine in elderly patients after laparoscopic abdominal tumor surgery: a randomized controlled trial (EUDRACT) - Oct 31, 2025
P=N/A, N=66, Not yet recruiting, Sponsor: Zhengzhou Central Hospital; Zhengzhou Central Hospital
- | Teysuno (gimeracil/oteracil/tegafur) / Nordic Group, Otsuka, AiRuiLi (adebrelimab) / Jiangsu Hengrui Pharma
New P1 trial: A single-arm, multicenter clinical study of neoadjuvant therapy of Adebrelimab combined with SOX for locally advanced resectable gastric or gastroesophageal adenocarcinoma (EUDRACT) - Oct 31, 2025
P1, N=35, Not yet recruiting, Sponsor: Lianyungang First People's Hospital; Lianyungang First People's Hospital
- | AiTan (rivoceranib) / HLB Bio Group, AiRuiKa (camrelizumab) / HLB Bio Group
New trial: A Prospective, Multicenter, Single-arm, Open-label Clinical Study to Evaluate the Efficacy and Safety of First-line Camrelizumab in Combination with Apatinib Mesylate and Radiotherapy in Advanced Mucosal Melanoma (EUDRACT) - Oct 31, 2025
P=N/A, N=30, Not yet recruiting, Sponsor: Nanjing Drum Tower Hospital; Nanjing Drum Tower Hospital
- | Avida (trastuzumab rezetecan) / Jiangsu Hengrui Pharma, AiRuiLi (adebrelimab) / Jiangsu Hengrui Pharma
New P2 trial: A Phase II Clinical Study of Trastuzumab Rezetecan (SHR-A1811) or in Combination With Adebrelimab (SHR-1316) for HER2-Expressing Locally Advanced or Metastatic Urothelial Carcinoma (la/mUC) (EUDRACT) - Oct 31, 2025
P2, N=96, Recruiting, Sponsor: Sun Yat-sen University Cancer Center; Sun Yat-sen University Cancer Center
- | AiTan (rivoceranib) / HLB Bio Group, Loqtorzi (toripalimab-tpzi) / Shanghai Junshi Biosci, Coherus Oncology
New trial: Exploratory study of perioperative treatment with apatinib plus toripalimab in combination with chemotherapy for non-small cell lung cancer (EUDRACT) - Oct 31, 2025
P=N/A, N=30, Not yet recruiting, Sponsor: Peking Union Medical College Hospital, Chinese Academy of Medical Sciences; Peking Union Medical College Hospital, Chinese Academy of Medical Sciences
- | AiRuiLi (adebrelimab) / Jiangsu Hengrui Pharma
New P2 trial: Adebrelimab Combined with Chemotherapy and Concurrent Radiotherapy as First-Line Treatment for ES-SCLC: A Single-Arm, Single-Center, Exploratory Clinical Study (EUDRACT) - Oct 31, 2025
P2, N=32, Not yet recruiting, Sponsor: West China Hospital of Sichuan University; West China Hospital of Sichuan University
- | AiTan (rivoceranib) / HLB Bio Group
New P4 trial: Immunotherapy combined with Apatinib and radiotherapy as first-line treatment for extensive-stage small cell lung cancer: A prospective, single-arm study. (EUDRACT) - Oct 31, 2025
P4, N=29, Not yet recruiting, Sponsor: Affiliated Hospital of Guangdong Medical University; Affiliated Hospital of Guangdong Medical University
- | Herceptin (trastuzumab) / Roche
New P4 trial, Monotherapy: MA-BC-II-110: An open, randomized controlled study comparing the efficacy of Rikang Trastuzumab combined with radiotherapy versus Rikang Trastuzumab monotherapy in patients with HER2-positive advanced breast cancer with brain metastases. (EUDRACT) - Oct 31, 2025
P4, N=224, Not yet recruiting, Sponsor: Henan Cancer Hospital; Henan Cancer Hospital
- | AiRuiKa (camrelizumab) / Elevar Therapeutics
New P2 trial: Exploratory Clinical Study of Camrelizumab Combined with Pirfenidone and Chemotherapy in the Treatment of Advanced Triple-Negative Breast Cancer (EUDRACT) - Oct 31, 2025
P2, N=12, Not yet recruiting, Sponsor: Harbin medical university cancer hospital; Harbin medical university cancer hospital
- | purinostat / Zenitar Biomedical, Tyvyt (sintilimab) / Innovent Biologics, Eli Lilly, AiTan (rivoceranib) / Elevar Therapeutics
New P1 trial: An exploratory clinical study evaluating the safety, tolerability, and efficacy of the combination of purinostat mesylate, sintilimab, and apatinib in the treatment of advanced/metastatic gastric cancer (EUDRACT) - Oct 31, 2025
P1, N=18, Not yet recruiting, Sponsor: West China Hospital, Sichuan University; West China Hospital, Sichuan University
- | AiSuDa (ivarmacitinib) / Jiangsu Hengrui Pharma, Arcutis
New P4 trial: A Randomized, Double-Blind, Placebo-Controlled, Multicenter Clinical Study on the Efficacy and Safety of JAK1 Inhibitor Ivarmacitinib in Combination with Topical Corticosteroids in the Treatment of Moderate-to-Severe Chronic Hand Eczema (EUDRACT) - Oct 31, 2025
P4, N=80, Not yet recruiting, Sponsor: The First Hospital of Hebei Medical University; The First Hospital of Hebei Medical University
- | AiRuiLi (adebrelimab) / Jiangsu Hengrui Pharma
New P4 trial: Clinical study of adebrelimab in the treatment of NSCLC treated with ICIs therapy (EUDRACT) - Oct 31, 2025
P4, N=30, Not yet recruiting, Sponsor: Anqing Municipal Hospital; Anqing Municipal Hospital
- | AiRuiKang (dalpiciclib) / Jiangsu Hengrui Pharma
New P2 trial: An Exploratory Study of Concurrent or Sequential Radiotherapy Combined with Dalpiciclib plus Endocrine Therapy in Early-Stage or Locoregionally Advanced Hormone Receptor-Positive/HER2-Negative Breast Cancer (EUDRACT) - Oct 31, 2025
P2, N=200, Not yet recruiting, Sponsor: Shanxi Cancer Hospital; Shanxi Cancer Hospital
- | AiRuiKa (camrelizumab) / HLB Bio Group, famitinib (SHR 1020) / Jiangsu Hengrui Pharma
New P2 trial: A prospective, multicenter, phase II study of famitinib maleate combined with camrelizumab and chemotherapy as neoadjuvant therapy for locally advanced cervical cancer. (EUDRACT) - Oct 31, 2025
P2, N=60, Not yet recruiting, Sponsor: Fujian Cancer Hospital; Fujian Cancer Hospital
- | AiRuiLi (adebrelimab) / Jiangsu Hengrui Pharma
New trial: Clinical Study of Adebrelimab Combined with Chemotherapy and Adebrelimab as Neoadjuvant Therapy for NSCLC (EUDRACT) - Oct 31, 2025
P=N/A, N=36, Not yet recruiting, Sponsor: Peking University People's Hospital; Peking University People's Hospital
- | AnDaJing (vunakizumab) / Jiangsu Hengrui Pharma, AiRuiLi (adebrelimab) / Jiangsu Hengrui Pharma
New P4 trial: Adebrelimab combined with vunakizumab for first-line maintenance treatment of extensive-stage small cell lung cancer: A prospective, single-center, single-arm clinical study (EUDRACT) - Oct 30, 2025
P4, N=43, Not yet recruiting, Sponsor: The First Affiliated Hospital of Nanjing Medical University; The First Affiliated Hospital of Nanjing Medical University
- | AiSuDa (ivarmacitinib) / Jiangsu Hengrui Pharma, Arcutis
New P4 trial: Ivarmacitinib for the Treatment of Sj (EUDRACT) - Oct 30, 2025
P4, N=30, Not yet recruiting, Sponsor: Union Hospital, Tongji Medical College, Huazhong University of Science and Technology; Union Hospital, Tongji Medical College, Huazhong University o
- | AiRuiLi (adebrelimab) / Jiangsu Hengrui Pharma
New P2 trial: A Single-Arm, Single-Center Phase II Clinical Study on Sequential Maintenance Therapy for Extensive-Stage Small Cell Lung Cancer Following First-Line Treatment with Adibelimab in Combination with Chemotherapy (EUDRACT) - Oct 30, 2025
P2, N=35, Recruiting, Sponsor: Hunan Cancer Hospital; Hunan Cancer Hospital
- | Zepsun (donafenib) / Suzhou Zelgen, Duoenda (mitoxantrone liposomal) / CSPC Pharma, Itari (linperlisib) / Shanghai YingLi Pharma
New P2 trial: Phase II Study Evaluating the Combination of Linperlisib, Azacitidine, and Liposomal Mitoxantrone in Treatment-Na (EUDRACT) - Oct 30, 2025
P2, N=30, Not yet recruiting, Sponsor: The First Affiliated Hospital of Soochow University; The First Affiliated Hospital of Soochow University
- | Avastin (bevacizumab) / Roche, Airuituo (bevacizumab biosimilar) / Jiangsu Hengrui Pharma
New P1 trial: Exploratory Study of Albumin-Bound Paclitaxel, Platinum, and Bevacizumab in EGFR-Mutant NSCLC with SCLC Transformation Post-EGFR-TKI Resistance (EUDRACT) - Oct 30, 2025
P1, N=8, Not yet recruiting, Sponsor: Zhejiang Cancer Hospital; Zhejiang Cancer Hospital
- | AiRuiLi (adebrelimab) / Jiangsu Hengrui Pharma
New P4 trial: Radiotherapy combined with NALIRI (irinotecan liposome injection II in conjunction with 5-FU/LV) and Adebrelimab as first-line treatment for unresectable locally advanced or oligometastatic malignant biliary tract tumors: A prospective, single-arm, single-center, exploratory study (EUDRACT) - Oct 30, 2025
P4, N=37, Not yet recruiting, Sponsor: Fudan University Affiliated Zhongshan Hospital; Fudan University Affiliated Zhongshan Hospital
- | AiRuiKang (dalpiciclib) / Jiangsu Hengrui Pharma, Enhertu (fam-trastuzumab deruxtecan-nxki) / Daiichi Sankyo, AstraZeneca
New P4 trial: Single arm, multicenter, exploratory phase II clinical study of new adjuvant therapy with Trastuzumab Deruxtecan for Injection for injection for early or locally advanced HR positive/HER2 low expression breast cancer with poor efficacy of dalpiciclib combined with endocrine therapy (EUDRACT) - Oct 30, 2025
P4, N=30, Not yet recruiting, Sponsor: Anyang Tumor Hospital; Anyang Tumor Hospital
- | albumin-bound paclitaxel / Generic mfg., gemcitabine / Generic mfg.
New P2 trial: Sodium Propionate combined with albumin paclitaxel, gemcitabine and PD-1 inhibitor for first-line treatment of advanced pancreatic cancer: a prospective study (EUDRACT) - Oct 30, 2025
P2, N=40, Not yet recruiting, Sponsor: The Second Affiliated Hospital Zhejiang University School of Medicine; The Second Affiliated Hospital Zhejiang University School of Medicine
- | trastuzumab rezetecan (SHR-A1811) / Jiangsu Hengrui Pharma
New P1/2 trial, Platinum sensitive: Phase I/II clinical study of SHR-A1811 combined regimen for injection in treatment of platinum-sensitive recurrent ovarian cancer (EUDRACT) - Oct 30, 2025
P1/2, N=42, Recruiting, Sponsor: Tongji Hospital, Tongji Medical College ,Huazhong University of Science and Technology; Tongji Hospital, Tongji Medical College ,Huazhong University o
- | Ruiqin (henagliflozin) / Jiangsu Hengrui Pharma
New P4 trial: Randomized, controlled and open label clinical trial of metformin Henagliflozin compound preparation in the treatment of type 2 diabetes mellitus patients with metabolic fatty liver disease and its effect on liver and pancreas fat content (EUDRACT) - Oct 30, 2025
P4, N=60, Not yet recruiting, Sponsor: The First People's Hospital of Foshan; The First People's Hospital of Foshan
- | AiSuTe (tegileridine) / Jiangsu Hengrui Pharma
New trial: Effect of Tegileridine Fumarate on Postoperative Recovery Quality in Patients Undergoing Laparoscopic Sleeve Gastrectomy:A randomized controlled double-blind clinical trial (EUDRACT) - Oct 30, 2025
P=N/A, N=70, Not yet recruiting, Sponsor: The First People's Hospital of Lianyungang; The First People
- | trastuzumab rezetecan (SHR-A1811) / Jiangsu Hengrui Pharma, Irene (pyrotinib) / Jiangsu Hengrui Pharma, Perjeta (pertuzumab) / Roche
New P4 trial, Monotherapy: A prospective clinical study of SHR-A1811 monotherapy or combined with pertuzumab in the treatment of HER2-positive advanced breast cancer with brain metastases after progression with pyrotinib (EUDRACT) - Oct 30, 2025
P4, N=40, Not yet recruiting, Sponsor: Changde First People's Hospital; Changde First People's Hospital
- | remimazolam tosylate (HR-7056) / Jiangsu Hengrui Pharma
New P4 trial: Safety and efficacy of repeated remimazolam tosilate sedation in patients receiving interstitial brachytherapy for cervical cancer and its impact on sleep quality (EUDRACT) - Oct 30, 2025
P4, N=100, Not yet recruiting, Sponsor: Sichuan Cancer Hospital; Sichuan Cancer Hospital
- Trodelvy (sacituzumab govitecan-hziy) / Gilead
Sacituzumab Govitecan Combined with Anti-angiogenic Therapy and Radiotherapy in a BRCA1-Mutated Triple-Negative Breast Cancer Patient with Multiple Recurrences: A Case Report (Exhibit Hall) - Oct 30, 2025 - Abstract #SABCS2025SABCS_2094;
P2
This case report highlights the potential efficacy of SG in combination with anti-angiogenic therapy and radiotherapy in treating BRCA1-mutated TNBC patients with multiple recurrences and brain metastases. However, further studies are needed to confirm these findings and to optimize the use of these agents in this subset of patients.
- Cycline Dipendent Kinase inhibitors 4/6 and endocrine therapy in the first line of treatment for HR+Her2- advanced breast cancer: a meta-analysis of the published real-world studies (Exhibit Hall) - Oct 30, 2025 - Abstract #SABCS2025SABCS_2076;
Any observed differences between R and P should be interpreted with consideration for the patient characteristics within the studies analysed. Further adjustment of the analysis using multiple variables is planned to assess inter-trial differences and mitigate bias inherent in real-world settings.
- tizetatug rezetecan (SHR-A1921) / Jiangsu Hengrui Pharma, AiRuiLi (adebrelimab) / Jiangsu Hengrui Pharma
Trop2-directed antibody-drug conjugate shr-a1921 combined with pd-l1 inhibitor adebrelimab for patients with advanced triple negative breast cancer: results from a phase 2, multi-cohort, open-label, non-controlled trial (Exhibit Hall) - Oct 30, 2025 - Abstract #SABCS2025SABCS_2001;
P2
The combination of SHR-A1921 and adebrelimab demonstrated promising anti-tumor efficacy and manageable safety in pretreated TNBC pts regardless of PD-L1 status, warranting further investigations in this population. Our exploration of ADCs combined with adebrelimab in HER2-negative advanced breast cancer is still ongoing.
- Irene (pyrotinib) / Jiangsu Hengrui Pharma
Pyrotinib plus capecitabine with or withoutradiotherapyin patients with HER2-positive metastatic breast cancer and brain metastases: Amulticenter, retrospective-prospective, real-world study in China (Post-PERMEATE) (Exhibit Hall) - Oct 30, 2025 - Abstract #SABCS2025SABCS_1979;
P=N/A
Therefore, future studies should further elucidate the characteristics of patients most likely to benefit from specific systemic-local treatment combinations and enabling personalized therapeutic strategies for HER2-positive breast cancer patients with BMs. These findings warrant prospective clinical investigation.Research Sponsor: None.
- Irene (pyrotinib) / Jiangsu Hengrui Pharma
Efficacy of cross-line therapy with anti-HER2 TKI in HER2-positive MBC: a multicenter real-world study (Exhibit Hall) - Oct 30, 2025 - Abstract #SABCS2025SABCS_1971;
Notably, patients with longer frontline PFS and those who switched TKI agents exhibited superior survival outcomes in subsequent treatment lines. Further prospective studies are warranted to confirm these findings.
- AiRuiKang (dalpiciclib) / Jiangsu Hengrui Pharma, Irene (pyrotinib) / Jiangsu Hengrui Pharma
Dalpiciclib Plus Pyrotinib Plus Letrozole for Patients with Estrogen Receptor-Positive and HER2-Positive Metastatic Breast Cancer (DAPLET) (Exhibit Hall) - Oct 30, 2025 - Abstract #SABCS2025SABCS_1959;
P2
The data supported this regimen as a potential alternative to standard chemotherapy-based approaches in this subtype. Efficacy of this regimen needs to be further evaluated in Simon stage II.
- Irene (pyrotinib) / Jiangsu Hengrui Pharma
Pyrotinib or placebo in combination with trastuzumab and docetaxel for untreated HER2-positive metastatic breast cancer: long-term survival results from the phase 3 PHILA study (Exhibit Hall) - Oct 30, 2025 - Abstract #SABCS2025SABCS_1944;
P3
Notably, with PyroHT, 5-year OS rate remained at 66% and nearly 30% of pts remained progression-free at 5 years. PyroHT treatment delayed time to onset of brain metastasis.
- AiTan (rivoceranib) / HLB Bio Group
Hmgcs2 promotes malignant phenotype and apatinib resistance in her2-negative breast cancer via the rab23/?-catenin/tcf signaling axis (Exhibit Hall) - Oct 30, 2025 - Abstract #SABCS2025SABCS_1621;
Mechanistic investigations revealed that RAB23-dependent ?-catenin/TCF activation served as the primary driver of carcinogenesis.Conclusion Our study revealed a critical role of HMGCS2 in mediating Apatinib resistance in HER2-negative breast cancer. Mechanistically, HMGCS2 promoted malignant progression in HER2-negative breast cancer by activating the ?-catenin/TCF transcriptional axis through RAB23-mediated signaling, highlighting HMGCS2 as a potential therapeutic target for precision oncology.
- AiRuiKang (dalpiciclib) / Jiangsu Hengrui Pharma, Irene (pyrotinib) / Jiangsu Hengrui Pharma, Herceptin (trastuzumab) / Roche
Neoadjuvant pyrotinib, trastuzumab, dalpiciclib, and exemestane in triple-positive breast cancer: a multicenter phase II trial (Exhibit Hall) - Oct 30, 2025 - Abstract #SABCS2025SABCS_1495;
This chemotherapy-free, quadruple-targeted neoadjuvant regimen demonstrated promising activity and manageable toxicity in early-stage TPBC. These data support further evaluation of this regimen as a potential alternative to standard chemotherapy-based neoadjuvant approaches in TPBC.
- Irene (pyrotinib) / Jiangsu Hengrui Pharma
A real-world study of pyrotinib as neoadjuvant therapy for HER2-positive breast cancer (Exhibit Hall) - Oct 30, 2025 - Abstract #SABCS2025SABCS_1491;
Background: A double-blind, randomized Phase 3 clinical study, PHEDRA, met its primary endpoint with a significantly higher tpCR rate than placebo in patients treated with pyrotinib, trastuzumab, and docetaxel in HER2-positive early or locally advanced breast cancer (41.0% vs. 22.0%, unilateral P< 0.0001). In this real-world study, neoadjuvant pyrotinib- containing regimens showed promising efficacy and safety in patients with HER2-positive breast cancer, further verify its effectiveness and safety in the real world.
- Irene (pyrotinib) / Jiangsu Hengrui Pharma, Aidixi (disitamab vedotin) / Pfizer
Efficacy and safety of disitamab vedotin combined with pyrotinib as neoadjuvant therapy for HER2-positive breast cancer: a phase II trial (Exhibit Hall) - Oct 30, 2025 - Abstract #SABCS2025SABCS_1478;
In this real-world study, neoadjuvant pyrotinib- containing regimens showed promising efficacy and safety in patients with HER2-positive breast cancer, further verify its effectiveness and safety in the real world. Post-surgery, adjuvant therapy (epirubicin 90 mg/m